Karyopharm Therapeutics (KPTI) Cash & Current Investments (2012 - 2025)

Karyopharm Therapeutics has reported Cash & Current Investments for 14 years, with the latest figure at $63.7 million in Q4 2025.

• For the quarter ending Q4 2025, Cash & Current Investments fell 55.9% year-over-year to $63.7 million; the trailing twelve-month figure through Dec 2025 stood at $63.7 million (down 55.9% YoY), and the FY2025 full-year result was $63.7 million, down 55.9% from the prior year.
• Cash & Current Investments for Q4 2025 stood at $63.7 million, up from $45.9 million in the prior quarter.
• The five-year high for Cash & Current Investments was $236.8 million in Q2 2023, with the low at $44.5 million in Q4 2021.
• Historically, Cash & Current Investments has averaged $123.6 million across 5 years, with a median of $138.7 million in 2022.
• Annual changes were most pronounced in 2022 — Cash & Current Investments sank 76.35% — and 2023, when it soared 233.84%.
• Karyopharm Therapeutics' Cash & Current Investments stood at $44.5 million in 2021, then jumped by 223.21% to $143.8 million in 2022, then jumped by 33.09% to $191.4 million in 2023, then fell by 24.5% to $144.5 million in 2024, then plunged by 55.9% to $63.7 million in 2025.
• The last three Cash & Current Investments figures came in at $63.7 million (Q4 2025), $45.9 million (Q3 2025), and $47.9 million (Q2 2025), per Business Quant data.